ArticleThe Journal of biological chemistry2026
STK31 enhances gallbladder cancer development by modulating DNA replication machinery.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) is a highly aggressive and insidious malignancy with a poor prognosis, primarily due to the lack of specific therapeutic targets and early diagnostic biomarkers. Therefore, identifying novel oncogenes involved in GBC and exploring targeted therapeutic strategies against them are of particular importance. STK31 is a cancer/testis antigen, but its biological function and mechanistic role in GBC remain unclear. This study investigates how STK31 influences GBC. STK31 expression in GBC and gastrointestinal tumors were analyzed using collected clinical samples and TCGA database, respectively. Its pro-tumorigenic functions were then confirmed by in vivo and in vitro assays, while downstream regulatory mechanisms were uncovered via multi-platform proteomic strategies. Molecular docking was employed to screen 1008 ChEMBL small molecules post STK31 functional validation. Significant upregulation of STK31 expression was observed in both GBC and gastrointestinal malignancies through our comprehensive analysis. STK31 depletion decreased GBC cell proliferation, migration, and induced G1/S phase arrest and cellular polyploidization. Gene Set Enrichment Analysis (GSEA) demonstrated that STK31 functionally correlates with core biological processes including DNA Replication, Cell Cycle, and Extracellular Matrix (ECM) Receptor Interaction. STK31 directly binds to both c-Myc and FOXP1, thereby regulating MCM and ITG family proteins to exert its biological function. In addition, STK31 influences the phosphorylation of c-Myc through its kinase activity. Atovaquone identified through molecular docking screening, binds STK31 and reduces its expression and kinase activity, demonstrating anti-tumor effects against GBC both in vitro and in vivo. We demonstrate that STK31 facilitates GBC progression through c-Myc/FOXP1-mediated DNA replication dysregulation. Its inhibition triggers lethal polyploidization, with ATO identified as a potential STK31-targeting drug candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.